Novel cathepsin c inhibitors and their use

A compound according to Formula I:

• wherein:
• each R1 is independently selected from the group consisting of:
• halo, C1-C4 alkyl, CF3, CN, NO2, —ORa, —OCF3, —C(O)NHRa, —C(O)ORa, —NRaRa, —NHC(O)Ra, or —NHC(O)NHRa;
• n is an integer from 0 to 4;
• R2a is H, halo, —C(O)Rx, —C(O)ORy, —C(O)NRaRy, —OC(O)Rx, —OC(O)NRaRy, —NRaRy, —NRaC(O)Rx, NRaC(O)R22, —NRaC(O)ORy, —NRaC(O)NRaRy, R20, R21, R22, R23, R24, —OH, —OR20, —OR21, —OR22, —OR23, or —OR24;
• —CN
• R2b is H or C1-C4 alkyl;
• or R2a and R2b taken together with the carbon atom to which they are attached form a C3-C7 cycloalkyl group;
• R2c is H or C1-C4 alkyl;
• R20 is C1-C4 alkyl;
• wherein said R20 is optionally substituted with one or more substituents independently selected from the group consisting of:
• halo, CF3, CN, NO2, R21, R22, R23, R24, —ORy, —C(O)Rx, —C(O)ORy, —C(O)NRaRy, —OC(O)Rx, —OC(O)NRaRy, —NRaRy, —NRaC(O)Rx, —NRaC(O)ORy, —NRaC(O)NRaRy;
• R21 is C3-C6 cycloalkyl;
• wherein said R21 is optionally substituted with one or more substituents independently selected from the group consisting of:
• CF3, Rc, —ORa, —OCF3, and —NRaRa;
• R22 is heterocycloalkyl;
• wherein said R22 is optionally substituted with one or more substituents independently selected from the group consisting of:
• CF3, Rc, —ORa, —OCF3, and —NRaRa;
• R23 is phenyl;
• wherein said R23 is optionally substituted with one or more substituents independently selected from the group consisting of:
• halo, CF3, CN, NO2, Rc, —ORa, —OCF3, —C(O)Rb, —C(O)ORa, —C(O)NRaRa, —OC(O)Rb, —OC(O)NRaRa, —NRaRa, —NRaC(O)Rb, —NRaC(O)ORa, —NRaC(O)NRaRa;
• R24 is monocyclic heteroaryl;
• wherein said R24 is optionally substituted with one or more substituents independently selected from the group consisting of:
• halo, CF3, CN, NO2, Rc, —ORa, —OCF3, —C(O)Rb, —C(O)ORa, —C(O)NRaRa, —OC(O)Rb, —OC(O)NRaRa, —NRaRa, —NRaC(O)Rb, —NRaC(O)ORa, —NRaC(O)NRaRa;
• R3 is H, R30, or R31;
• R30 is C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl;
• wherein said R30 is optionally substituted with one or more substituents independently selected from the group consisting of:
• CF3, Re, Rf, Rg, —ORa, CN, —OCF3, —ORf, —ORg, —OR31, and —NRaRa;
• R31 is C3-C6 cycloalkyl;
• wherein said R31 is optionally substituted with one or more substituents independently selected from the group consisting of:
• Rb, —ORa, —OCF3, and —NRaRa;
• each Ra is independently H or C1-C4 alkyl;
• each Rb is independently C1-C4 alkyl;
• each Re is independently C1-C4 alkyl;
• wherein said C1-C4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of:
• CF3, —ORa, OCF3, and —NRaRa;
• each Rd is independently C1-C4 alkyl;
• wherein said C1-C4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of:
• CF3, —ORa, OCF3, —NRaRa, Re, and Rf;
• each Re is independently phenyl or heteroaryl optionally substituted with one or more substituents independently selected from the group consisting of:
• halo, CF3, Rb, R23, R24, —ORa, OCF3, and —NRaRa;
• each Rf is independently monocyclic heteroaryl optionally substituted with one or more substituents independently selected from the group consisting of:
• halo, CF3, Rb, R23, R24, —ORa, OCF3, and —NRaRa;
• each Rg is independently napthyl optionally substituted with one or more substituents independently selected from the group consisting of:
• halo, CF3, Rb, —ORa, OCF3, and —NRaRa;
• each Rh is independently C3-C6 cycloalkyl optionally substituted with one or more substituents independently selected from the group consisting of:
• Rb, —ORa, —OCF3, and —NRaRa;
• each Rx is Rd, Re, Rf, Rg, or Rh;
• and
• each Ry is H, Rd, Re, Rf, Rg, or Rh;
• or
• a salt thereof.